New Publication Highlights Basic Science Supporting Simufilam
June 12 2023 - 9:15AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced a new science publication in Drug Development Research, a
peer-reviewed journal. This article reviews certain
receptor-protein interactions, including an overview of basic
science supporting simufilam. Simufilam is Cassava Sciences’ oral
investigational drug candidate that is currently in Phase 3
clinical trials in patients with mild-to-moderate Alzheimer's
disease dementia.
“This paper highlights the role of altered
filamin A and its receptor interactions in Alzheimer's disease,”
said Lindsay Burns, PhD, first author and Cassava Sciences’ Senior
VP, Neuroscience. “We believe the theme of receptor-protein
interactions is critical to the proposed mechanism of action of
simufilam, our small molecule drug candidate for patients with
Alzheimer's disease.”
The review article was published on-line June 8,
2023, ahead of print and is titled “Targeting alpha7 nicotinic
acetylcholine receptors and their protein interactions in
Alzheimer’s disease drug development.” The abstract is currently
available on-line on the publisher’s website:
https://doi.org/10.1002/ddr.22085.
Access to the full text is subject to the
publisher’s copyright and fee policies. The citation is: “Burns LH,
Pei Z, Wang HY. Targeting α7 nicotinic acetylcholine receptors and
their protein interactions in Alzheimer's disease drug development.
Drug Dev Res. 2023 Jun 8. doi: 10.1002/ddr.22085. Epub ahead of
print. PMID: 37291958.”
About SimufilamSimufilam is a
novel drug candidate designed to treat and slow the progression of
Alzheimer’s disease. Simufilam binds tightly to an altered
conformation of the filamin A protein (FLNA) that is present in the
brain of the Alzheimer’s patient and is critical to the toxicity of
Aβ42. Simufilam is wholly owned by Cassava Sciences, without
royalty or payment obligation to any third party.
About Cassava Sciences,
Inc.Cassava Sciences is a clinical-stage biotechnology
company based in Austin, Texas. Our mission is to detect and treat
neurodegenerative diseases, such as Alzheimer’s disease. Our novel
science is based on stabilizing—but not removing—a critical protein
in the brain. Our product candidates have not been approved by any
regulatory authority, and their safety, efficacy or other desirable
attributes have not been established. For more information, please
visit our website: https://www.CassavaSciences.com
For More Information Contact:Eric Schoen, Chief
Financial Officer(512) 501-2450, or ESchoen@CassavaSciences.com
Cautionary Note Regarding
Forward-Looking Statements: This news release contains
forward-looking statements, including statements made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, that may include but are not limited to: our
basic research in support of simufilam; the design, scope, conduct
or intended purpose of our Phase 3 program of simufilam in patients
with Alzheimer's disease; the safety or expected effects of
simufilam in Alzheimer’s disease, if any; any expected clinical
results of Phase 3 studies; the treatment of people with
Alzheimer’s disease dementia; the safety or efficacy of simufilam
in people with Alzheimer’s disease dementia; verbal commentaries
made by our employees; and potential benefits, if any, of the our
product candidates. These statements may be identified by words
such as “may,” “anticipate,” “believe,” “could,” “expect,”
“forecast,” “intend,” “plan,” “possible,” “potential,” and other
words and terms of similar meaning.
Simufilam is our investigational product
candidates. It is not approved by any regulatory authority in any
jurisdiction and their safety, efficacy or other desirable
attributes have not been established in patients. Drug development
and commercialization involve a high degree of risk, and only a
small number of research and development programs result in
commercialization of a product. Clinical results from our prior
studies may not be indicative of results of future or larger scale
clinical trials and do not ensure regulatory approval. You should
not place undue reliance on these statements or any scientific data
we present or publish.
Such statements are based largely on our current
expectations and projections about future events. Such statements
speak only as of the date of this news release and are subject to a
number of risks, uncertainties and assumptions, including, but not
limited to, those risks relating to the ability to conduct or
complete clinical studies on expected timelines, to demonstrate the
specificity, safety, efficacy or potential health benefits of our
product candidates, any unanticipated impacts of inflation on our
business operations, and including those described in the section
entitled “Risk Factors” in our Annual Report on Form 10-K for the
year ended December 31, 2022, and future reports to be filed with
the SEC. The foregoing sets forth many, but not all, of the factors
that could cause actual results to differ from expectations in any
forward-looking statement. In light of these risks, uncertainties
and assumptions, the forward-looking statements and events
discussed in this news release are inherently uncertain and may not
occur, and actual results could differ materially and adversely
from those anticipated or implied in the forward-looking
statements. Accordingly, you should not rely upon forward-looking
statements as predictions of future events. Except as required by
law, we disclaim any intention or responsibility for updating or
revising any forward-looking statements contained in this news
release. For further information regarding these and other risks
related to our business, investors should consult our filings with
the SEC, which are available on the SEC's website at
www.sec.gov.
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Apr 2024 to May 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From May 2023 to May 2024